Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Buy
94
THNR Quote, Financials, Valuation and Earnings
Last price:
$25.75
Seasonality move
:
-6.14%
Day range:
$25.75 - $26.02
52-week range:
$18.56 - $26.30
Dividend yield:
1.6%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
1.6K
Avg. volume:
2.7K
1-year change:
14.41%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
-- | -- | -- | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | -- | -- | -- | -- |
|
IBRN
iShares Neuroscience and Healthcare ETF
|
-- | -- | -- | -- | -- |
|
JDOC
JPMorgan Healthcare Leaders ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
$25.82 | -- | -- | -- | $0.41 | 1.6% | -- |
|
AGNG
Global X Aging Population ETF
|
$36.80 | -- | -- | -- | $0.17 | 0.85% | -- |
|
IBRN
iShares Neuroscience and Healthcare ETF
|
$31.52 | -- | -- | -- | $0.32 | 1.02% | -- |
|
JDOC
JPMorgan Healthcare Leaders ETF
|
$58.79 | -- | -- | -- | $0.51 | 0.87% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
-- | 0.647 | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | 0.276 | -- | -- |
|
IBRN
iShares Neuroscience and Healthcare ETF
|
-- | 0.904 | -- | -- |
|
JDOC
JPMorgan Healthcare Leaders ETF
|
-- | 0.222 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
-- | -- | -- | -- | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | -- | -- | -- | -- | -- |
|
IBRN
iShares Neuroscience and Healthcare ETF
|
-- | -- | -- | -- | -- | -- |
|
JDOC
JPMorgan Healthcare Leaders ETF
|
-- | -- | -- | -- | -- | -- |
Amplify Weight Loss Drug & Treatment ETF vs. Competitors
-
Which has Higher Returns THNR or AGNG?
Global X Aging Population ETF has a net margin of -- compared to Amplify Weight Loss Drug & Treatment ETF's net margin of --. Amplify Weight Loss Drug & Treatment ETF's return on equity of -- beat Global X Aging Population ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- AGNGGlobal X Aging Population ETF-- -- -- -
What do Analysts Say About THNR or AGNG?
Amplify Weight Loss Drug & Treatment ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Global X Aging Population ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Amplify Weight Loss Drug & Treatment ETF has higher upside potential than Global X Aging Population ETF, analysts believe Amplify Weight Loss Drug & Treatment ETF is more attractive than Global X Aging Population ETF.
Company Buy Ratings Hold Ratings Sell Ratings THNRAmplify Weight Loss Drug & Treatment ETF0 0 0 AGNGGlobal X Aging Population ETF0 0 0 -
Is THNR or AGNG More Risky?
Amplify Weight Loss Drug & Treatment ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Global X Aging Population ETF has a beta of 0.740, suggesting its less volatile than the S&P 500 by 26.042%.
-
Which is a Better Dividend Stock THNR or AGNG?
Amplify Weight Loss Drug & Treatment ETF has a quarterly dividend of $0.41 per share corresponding to a yield of 1.6%. Global X Aging Population ETF offers a yield of 0.85% to investors and pays a quarterly dividend of $0.17 per share. Amplify Weight Loss Drug & Treatment ETF pays -- of its earnings as a dividend. Global X Aging Population ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios THNR or AGNG?
Amplify Weight Loss Drug & Treatment ETF quarterly revenues are --, which are smaller than Global X Aging Population ETF quarterly revenues of --. Amplify Weight Loss Drug & Treatment ETF's net income of -- is lower than Global X Aging Population ETF's net income of --. Notably, Amplify Weight Loss Drug & Treatment ETF's price-to-earnings ratio is -- while Global X Aging Population ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amplify Weight Loss Drug & Treatment ETF is -- versus -- for Global X Aging Population ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- -- AGNGGlobal X Aging Population ETF-- -- -- --
-
Which has Higher Returns THNR or IBRN?
iShares Neuroscience and Healthcare ETF has a net margin of -- compared to Amplify Weight Loss Drug & Treatment ETF's net margin of --. Amplify Weight Loss Drug & Treatment ETF's return on equity of -- beat iShares Neuroscience and Healthcare ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- IBRNiShares Neuroscience and Healthcare ETF-- -- -- -
What do Analysts Say About THNR or IBRN?
Amplify Weight Loss Drug & Treatment ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand iShares Neuroscience and Healthcare ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Amplify Weight Loss Drug & Treatment ETF has higher upside potential than iShares Neuroscience and Healthcare ETF, analysts believe Amplify Weight Loss Drug & Treatment ETF is more attractive than iShares Neuroscience and Healthcare ETF.
Company Buy Ratings Hold Ratings Sell Ratings THNRAmplify Weight Loss Drug & Treatment ETF0 0 0 IBRNiShares Neuroscience and Healthcare ETF0 0 0 -
Is THNR or IBRN More Risky?
Amplify Weight Loss Drug & Treatment ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison iShares Neuroscience and Healthcare ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock THNR or IBRN?
Amplify Weight Loss Drug & Treatment ETF has a quarterly dividend of $0.41 per share corresponding to a yield of 1.6%. iShares Neuroscience and Healthcare ETF offers a yield of 1.02% to investors and pays a quarterly dividend of $0.32 per share. Amplify Weight Loss Drug & Treatment ETF pays -- of its earnings as a dividend. iShares Neuroscience and Healthcare ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios THNR or IBRN?
Amplify Weight Loss Drug & Treatment ETF quarterly revenues are --, which are smaller than iShares Neuroscience and Healthcare ETF quarterly revenues of --. Amplify Weight Loss Drug & Treatment ETF's net income of -- is lower than iShares Neuroscience and Healthcare ETF's net income of --. Notably, Amplify Weight Loss Drug & Treatment ETF's price-to-earnings ratio is -- while iShares Neuroscience and Healthcare ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amplify Weight Loss Drug & Treatment ETF is -- versus -- for iShares Neuroscience and Healthcare ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- -- IBRNiShares Neuroscience and Healthcare ETF-- -- -- --
-
Which has Higher Returns THNR or JDOC?
JPMorgan Healthcare Leaders ETF has a net margin of -- compared to Amplify Weight Loss Drug & Treatment ETF's net margin of --. Amplify Weight Loss Drug & Treatment ETF's return on equity of -- beat JPMorgan Healthcare Leaders ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- JDOCJPMorgan Healthcare Leaders ETF-- -- -- -
What do Analysts Say About THNR or JDOC?
Amplify Weight Loss Drug & Treatment ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand JPMorgan Healthcare Leaders ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Amplify Weight Loss Drug & Treatment ETF has higher upside potential than JPMorgan Healthcare Leaders ETF, analysts believe Amplify Weight Loss Drug & Treatment ETF is more attractive than JPMorgan Healthcare Leaders ETF.
Company Buy Ratings Hold Ratings Sell Ratings THNRAmplify Weight Loss Drug & Treatment ETF0 0 0 JDOCJPMorgan Healthcare Leaders ETF0 0 0 -
Is THNR or JDOC More Risky?
Amplify Weight Loss Drug & Treatment ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison JPMorgan Healthcare Leaders ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock THNR or JDOC?
Amplify Weight Loss Drug & Treatment ETF has a quarterly dividend of $0.41 per share corresponding to a yield of 1.6%. JPMorgan Healthcare Leaders ETF offers a yield of 0.87% to investors and pays a quarterly dividend of $0.51 per share. Amplify Weight Loss Drug & Treatment ETF pays -- of its earnings as a dividend. JPMorgan Healthcare Leaders ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios THNR or JDOC?
Amplify Weight Loss Drug & Treatment ETF quarterly revenues are --, which are smaller than JPMorgan Healthcare Leaders ETF quarterly revenues of --. Amplify Weight Loss Drug & Treatment ETF's net income of -- is lower than JPMorgan Healthcare Leaders ETF's net income of --. Notably, Amplify Weight Loss Drug & Treatment ETF's price-to-earnings ratio is -- while JPMorgan Healthcare Leaders ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amplify Weight Loss Drug & Treatment ETF is -- versus -- for JPMorgan Healthcare Leaders ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- -- JDOCJPMorgan Healthcare Leaders ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
69
RGC alert for Jan 7
Regencell Bioscience Holdings Ltd. [RGC] is up 58.95% over the past day.
Buy
69
WDC alert for Jan 7
Western Digital Corp. [WDC] is down 8.88% over the past day.
Buy
75
DRUG alert for Jan 7
Bright Minds Biosciences, Inc. [DRUG] is up 2.99% over the past day.
